{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2007"],"condition":["Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2520341"],"location":["Austria","Germany"],"study_start_month":["1"],"keyword":["Irinotecan","Campto","Flourouracil","Folinsäure","Erbitux","Avastin"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Randomisierte Studie \nzur Wirksamkeit von FOLFIRI  \nin Kombination mit Cetuximab vs. Bevacizumab in der Erstlinien-Behandlung des metastasierten kolorektalen Karzinoms\n\nEnglish translation:\nRandomised study for efficiency of FOLFIRI in combination with Cetuximab vs. Bevacizumab in first-line-therapy of metastatic colorectal cancer","description":"Primary objectives: Comparative validation of antitumor efficacy measured by objective remissionrate defined by RECIST-criteria (OR= CR+ PR), assessed within intent-to-treat-collective.\nPrimary endpoints: Progression of metastatic colorectal cancer or patient’s death","dates":{"creation":"2007-01-15"},"accession":"2520341","cross_references":{"EU Clinical Trials Register":["2006-004030-32"]}}